Fiocruz
Pharmaceutical company Gilead Sciences has signed a memorandum of understanding with Farmanguinhos, part of Fiocruz, to assess technology transfer and local production of lenacapavir, a semestral HIV prevention injection. The deal aims to lower costs and improve accessibility in Brazil, though it is not yet a formal commitment. Anvisa approved the drug on January 12, 2026.
Ti AI ṣe iroyin
Severe flu cases are rising in Brazil's Southeast region and beginning to spread to Bahia, according to Fiocruz's Infogripe bulletin. The influenza A virus is the leading cause of deaths from Severe Acute Respiratory Syndrome (SRAG) in the country so far. The data covers epidemiological week 44, from October 26 to November 1.